InCephalo Therapeutics
Phase 1/2InCephalo engineers compartment-locked biologics to treat glioblastoma. Our C-Lock™ technology delivers potent immune activation to brain tumors without the risks of systemic exposure.
Founded
2018
Focus
BiologicsDrug Delivery
About
InCephalo engineers compartment-locked biologics to treat glioblastoma. Our C-Lock™ technology delivers potent immune activation to brain tumors without the risks of systemic exposure.
Funding History
1Total raised: $4.2M
Seed$4.2MUndisclosedNov 15, 2022
Company Info
TypePrivate
Founded2018
LocationBasel, Switzerland
StagePhase 1/2
Contact
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile